3rd Annual University of Chicago Multidisciplinary Breast Cancer Symposium

3rd Annual University of Chicago Multidisciplinary Breast Cancer Symposium is organized by Meeting Achievements, LLC and The University of Chicago - Center for Continuing Medical Education and will be held on Mar 06, 2026 at The Westin Michigan Avenue Chicago, Chicago, Illinois, United States of America.

Description:
Expert faculty will share the latest evidence-based strategies in medical, surgical, reconstructive, and radiation oncology, along with insights into practice-changing advances from the past year. 
Highlights include:

• Best practices and current controversies in breast cancer management
• Cutting-edge applications of ctDNA and liquid biopsy technologies
• Effective solutions for challenging side effects, including sexual dysfunction, hair loss, and lymphedema
• A look ahead at late-phase therapies poised for clinical adoption 

By the end of this highly interactive activity, you’ll walk away with practical tools to sharpen your decision-making, enhance clinical performance, and deliver better outcomes for patients across all breast cancer subtypes.

Learning Objectives
After this activity, participants will be able to:

• Apply evidence-based approaches to the use of ctDNA and liquid biopsy in clinical decision-making for patients with breast cancer.
• Implement supportive care strategies to address sexual dysfunction, hair loss, and lymphedema in breast cancer survivors.
• Analyze practice-changing developments from the past year to guide clinical decision-making across medical, surgical, and radiation oncology.
• Integrate recent late-phase clinical trial data to develop patient-specific treatment strategies in breast cancer management.
• Evaluate evolving surgical strategies, including axillary de-escalation, to optimize outcomes and inform individualized patient care.
• Develop management plans for toxicities associated with novel breast cancer therapies, including antibody-drug conjugates and endocrine therapies.
• Design individualized care plans for patients with complex or guideline-limited breast cancer presentations using case-based clinical reasoning.